Growth Hormone Interactions: Alcohol, Caffeine, Food & Other Compounds

What This Page Covers

Growth hormone (GH) is a pituitary hormone whose therapeutic use is defined by a set of recognised clinical indications, catalogued in a 2022 review of clinical indications for growth hormone therapy in Advances in Pediatrics. Questions about "interactions" — with alcohol, with caffeine, with food and fasting, or with other compounds — arrive as a single cluster, but the published record does not map onto them evenly. Some pairings have dedicated experiments: growth hormone administered alongside testosterone in a rat model, or a ghrelin-receptor drug tested against placebo in people with alcohol use disorder. Others, notably caffeine, have no interaction study at all in the literature summarised here, and this page says so rather than filling the gap with inference presented as fact. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about hormones, medications or health conditions. A broader description of the hormone itself is in the PeptideU growth hormone overview.

Alcohol and the Growth Hormone Axis: What Studies Report

No trial in this evidence set administered growth hormone together with alcohol and measured the result. The two literatures that intersect are separate. On the alcohol side, a 2022 review in the Journal of Clinical and Experimental Hepatology described the pathogenesis of alcohol-associated liver disease, setting out the mechanisms through which chronic alcohol exposure damages hepatic tissue (PMID 36340300). Researchers working on the growth hormone axis often note that the liver is the organ where much of the downstream signalling of growth hormone is transduced; that observation is mechanistic reasoning, and the review cited here characterised liver injury, not growth hormone pharmacology.

The most direct experimental link between alcohol and the growth hormone system involves the growth hormone secretagogue receptor (GHSR), the receptor for ghrelin. A randomized, double-blind, placebo-controlled study published in JCI Insight in 2024 tested a GHSR blocker against placebo in people with alcohol use disorder (PMID 39704175). The study is notable because it treated the growth hormone secretagogue receptor as a pharmacological target in an alcohol population — an approach that exists precisely because researchers had reason to think the ghrelin–GHSR system participates in alcohol-related behaviour. That trial examined a receptor blocker, not administered growth hormone, and its design does not describe what happens when exogenous growth hormone and alcohol are present together.

Anyone reading these two papers as a combined answer to "growth hormone and alcohol" is bridging a gap the studies themselves did not bridge. The honest summary of the evidence is that a receptor in the growth hormone secretagogue family has been studied in alcohol use disorder (PMID 39704175) and that alcohol's hepatic pathology has been reviewed in detail (PMID 36340300), while the pairing itself remains unstudied here.

Caffeine and Growth Hormone: What the Literature Covers

There is no caffeine–growth hormone interaction study in the verified literature summarised on this page. No trial, review or animal experiment in this set administered caffeine alongside growth hormone, measured growth hormone secretion after caffeine, or assessed whether caffeine alters growth hormone pharmacokinetics. Stating that plainly is more useful than assembling a plausible-sounding answer from unrelated papers.

What researchers do when no interaction study exists is reason from mechanism, and that reasoning should be labelled as what it is: hypothesis, not evidence. Growth hormone secretion is pulsatile and is shaped by sleep architecture, feeding state and neuroendocrine input; reviews of endocrine regulation across the lifespan have described how hormonal axes shift with age and physiological context (PMID 37600699). Because caffeine is a central nervous system stimulant that affects sleep, a mechanistic argument can be constructed in either direction — but the review cited here addressed endocrine regulation in aging, not caffeine, and it cannot be used to predict an interaction. No dose, no effect size and no timing relationship for caffeine and growth hormone is supported by this evidence set.

Food, Fasting and Feeding Signals

Ghrelin, the GH secretagogue receptor, and food acquisition

The clearest food-related biology in the growth hormone literature runs through ghrelin, the endogenous ligand at the growth hormone secretagogue receptor. A 2020 comparative physiology study examined ghrelin and food acquisition in wild and cultured Japanese eel, reporting on how feeding context related to the ghrelin system in that species (PMID 32294535). Comparative work of this kind is used by researchers to argue that the ghrelin–GHSR system is an evolutionarily conserved feeding signal rather than a mammal-specific curiosity; it does not describe human fasting protocols.

Growth hormone signalling in appetite circuits

A 2019 study in Molecular and Cellular Endocrinology reported that growth hormone/STAT5 signalling in proopiomelanocortin (POMC) neurons regulated glucoprivic hyperphagia (PMID 31494175). In plain terms, the study located growth hormone receptor signalling inside a hypothalamic neuron population that governs feeding responses to falling glucose availability. That is a food-related interaction in the most literal sense — the hormone's signalling pathway sits within the circuitry that responds to energy deficit — but the work was conducted in a laboratory model and describes neural regulation, not a dietary recommendation.

Human data on extreme feeding drive comes from Prader–Willi syndrome, a condition in which growth hormone therapy is an established indication. A 2025 cross-sectional study of 210 Chinese patients examined food responsiveness, food addiction and hyperphagia in Prader–Willi syndrome (PMID 41210500). The study characterised eating behaviour in that population; it is cited here because it is one of the few large human datasets sitting at the intersection of growth hormone-treated conditions and food behaviour, not because it measured a growth hormone–food interaction directly.

Diet composition and GH-dependent outcomes

Diet content, as opposed to meal timing, has been tested against growth hormone signalling in mice. A 2014 study in Aging Cell reported that growth hormone signalling was necessary for the lifespan extension produced by dietary methionine manipulation (PMID 25234161). The finding matters conceptually: it positions the growth hormone axis as a required intermediary for a diet effect, meaning the diet and the hormone were not independent variables in that model. Researchers cite this kind of result when arguing that nutritional interventions and endocrine signalling cannot be evaluated in isolation, and reviews of endocrine regulation in aging have taken up similar themes (PMID 37600699).

Combinations With Other Compounds

Growth hormone with testosterone

A 2018 study in Endocrine Connections examined the effects of combined growth hormone and testosterone treatments in a rat model of micropenis (PMID 30352406). This is one of the few explicit combination experiments in the verified set: the researchers compared combined hormonal treatment in an animal model of a developmental condition. It is preclinical, species-specific and disease-model-specific, and it does not establish how the two hormones behave together in humans.

Growth hormone secretagogue receptor and GLP-1 drugs

A 2025 study in Molecular and Cellular Endocrinology reported that liraglutide induced enhanced suppression of food intake in mice lacking the growth hormone secretagogue receptor (PMID 40738311). In other words, removing the GHSR did not blunt the GLP-1 receptor agonist's effect on feeding — the suppression was greater in the knockout animals. The study used genetic deletion rather than a co-administered growth hormone product, so it speaks to crosstalk between two appetite-regulating receptor systems rather than to combining medications. Alongside the placebo-controlled GHSR blocker trial in alcohol use disorder (PMID 39704175), it illustrates that most current "combination" research targets the secretagogue receptor rather than the hormone itself.

Interaction-Relevant Signals: What Studies Report

Two reviews frame why interaction questions around this axis receive attention. A 2023 review in Endocrine-Related Cancer discussed targeting growth hormone in cancer and future perspectives for that approach (PMID 37310137), reflecting sustained research interest in the growth hormone axis as a driver of proliferative signalling. A 2015 update in The Open Dentistry Journal reviewed growth hormone and craniofacial tissues, summarising how the hormone relates to tissue growth in that region (PMID 25674165). Neither review examined alcohol, caffeine or dietary co-exposures; both are cited to indicate the breadth of tissues and outcomes researchers associate with the axis. The clinical boundaries of therapeutic use are set out in the 2022 indications review (PMID 35985710).

Where the Evidence Stops

• Alcohol: no co-administration study; the closest evidence is a placebo-controlled GHSR blocker trial in alcohol use disorder (PMID 39704175) and a review of alcohol-associated liver disease pathogenesis (PMID 36340300).
• Caffeine: no interaction study in this evidence set; mechanistic speculation only, explicitly labelled as such.
• Fasting windows and meal timing: not tested in these papers; the food-related evidence concerns ghrelin signalling (PMID 32294535), hypothalamic circuits (PMID 31494175) and diet composition in mice (PMID 25234161).
• Compound combinations: one preclinical hormone pairing (PMID 30352406) and one receptor-knockout crosstalk experiment with liraglutide (PMID 40738311).

Where a question has no study behind it, the absence is itself the finding. Readers with clinical questions about hormones, alcohol intake, stimulants or medication combinations should direct them to a licensed physician who can assess individual circumstances.

References

• Clinical Indications for Growth Hormone Therapy (Advances in Pediatrics, 2022)
• Pathogenesis of Alcohol-Associated Liver Disease (Journal of Clinical and Experimental Hepatology, 2022)
• A randomized, double-blind, placebo-controlled study of a GHSR blocker in people with alcohol use disorder (JCI Insight, 2024)
• Liraglutide induces enhanced suppression of food intake in mice lacking the growth hormone secretagogue receptor (Molecular and Cellular Endocrinology, 2025)
• Effects of combined growth hormone and testosterone treatments in a rat model of micropenis (Endocrine Connections, 2018)
• Growth Hormone and Craniofacial Tissues. An update (The Open Dentistry Journal, 2015)
• Food responsiveness, addiction, and hyperphagia in Prader-Willi syndrome: a cross-sectional study of 210 Chinese patients (Frontiers in Endocrinology, 2025)
• Ghrelin and food acquisition in wild and cultured Japanese eel (Anguilla japonica) (Comparative Biochemistry and Physiology Part A, 2020)
• Targeting growth hormone in cancer: future perspectives (Endocrine-Related Cancer, 2023)
• Growth hormone signaling is necessary for lifespan extension by dietary methionine (Aging Cell, 2014)
• Growth hormone/STAT5 signaling in proopiomelanocortin neurons regulates glucoprivic hyperphagia (Molecular and Cellular Endocrinology, 2019)
• Aging under endocrine hormone regulation (Frontiers in Endocrinology, 2023)